Institute of technology, Bavarian Ministry of the Interior, Innovation, Education, ISIN, CEO, WKN, Biome, Pharmacist, Health, Conditional sentence, Patient, Marketing, Urinary tract infection, ACE2, German, TUM, Industry, Physician, Regional development, Severe acute respiratory syndrome coronavirus 2, The Economist, Federal Ministry of Science and Technology, MDL, Investor, COVID-19, EUR, BMBF, Ophthalmology, Pleasure, Free State (province), Free, Rivers State Ministry of Youth Development, Economy, Technical University of Munich, Fine chemical, Pharmaceutical industry, Vaccine
Wednesday, September 15, 2021 - 8:01am
Press Release // September 15, 2021
- Press Release // September 15, 2021
Munich - Formycon AG (ISIN: DE000A1EWVY8/ WKN: A1EWVY) yesterday received the Pharma Trend Image & Innovation "Most Innovative Product(R)" Award in the category of Leap Innovations for its COVID-19 drug development FYB207.
- For what is now the 22nd time, the Pharma Trend Image & Innovation Awards, also known in the industry as the Pharma Oscars, were presented in various categories at a celebratory awards ceremony under the patronage of Bavarian Health Minister Klaus Holetschek, MdL.
- "Receiving the prestigious Pharma Trend Image & Innovation 'Most Innovative Product(R)' Award for Leap Innovations is a great pleasure and encourages us in our innovative COVID-19 drug development.
- Based on its extensive experience in the development of biopharmaceutical drugs, the company is also working on the development of an innovative COVID-19 drug.